S. Kyle

发表

Potentiation of temozolomide and topotecan growth inhibition and cytotoxicity by novel poly(adenosine diphosphoribose) polymerase inhibitors in a panel of human tumor cell lines.

N. Curtin, B. Durkacz, D. Newell, 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

The synergistic interaction of MEK and PI3K inhibitors is modulated by mTOR inhibition

R. Maxwell, D. Newell, E. Haagensen, 2012, British Journal of Cancer.

Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase

Thomas Helleday, N. Curtin, T. Helleday, 2005, Nature.

Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase

Thomas Helleday, Nicola J. Curtin, N. Curtin, 2007, Nature.

Low nicotinamide mononucleotide adenylyltransferase activity in a tiazofurin-resistant cell line: effects on NAD metabolism and DNA repair.

S. Boulton, B. Durkacz, S. Kyle, 1997, British Journal of Cancer.

Potentiation of cytotoxic drug activity in human tumour cell lines, by amine-substituted 2-arylbenzimidazole-4-carboxamide PARP-1 inhibitors.

N. Curtin, R. Griffin, B. Golding, 2004, Bioorganic & medicinal chemistry letters.

Vasoactivity of AG014699, a Clinically Active Small Molecule Inhibitor of Poly(ADP-ribose) Polymerase: a Contributory Factor to Chemopotentiation In vivo?

N. Curtin, B. Telfer, D. Hirst, 2009, Clinical Cancer Research.

Novel Poly(ADP-ribose) Polymerase-1 Inhibitor, AG14361, Restores Sensitivity to Temozolomide in Mismatch Repair-Deficient Cells

N. Curtin, B. Durkacz, D. Newell, 2004, Clinical Cancer Research.

Preclinical Development The Clinically Active PARP Inhibitor AG 014699 Ameliorates Cardiotoxicity but Does Not Enhance the Ef fi cacy of Doxorubicin , despite Improving Tumor Perfusion and Radiation Response in Mice

N. Curtin, B. Telfer, K. Williams, 2011 .

The Clinically Active PARP Inhibitor AG014699 Ameliorates Cardiotoxicity but Does Not Enhance the Efficacy of Doxorubicin, despite Improving Tumor Perfusion and Radiation Response in Mice

N. Curtin, B. Telfer, K. Williams, 2011, Molecular Cancer Therapeutics.

Mechanisms of enhancement of cytotoxicity in etoposide and ionising radiation-treated cells by the protein kinase inhibitor wortmannin.

S. Boulton, B. Durkacz, S. Kyle, 2000, European journal of cancer.

PARP inhibitor rucaparib induces changes in NAD levels in cells and liver tissues as assessed by MRS

N. Curtin, R. Maxwell, D. Newell, 2017, NMR in biomedicine.

Interactive effects of inhibitors of poly(ADP-ribose) polymerase and DNA-dependent protein kinase on cellular responses to DNA damage.

S. Boulton, B. Durkacz, S. Kyle, 1999, Carcinogenesis.

Chemical Therapeutics Preclinical Evaluation of a Novel ATM Inhibitor , KU 59403 , In Vitro and In Vivo in p 53 Functional and Dysfunctional Models of Human Cancer

N. Curtin, A. Lau, Yan Zhao, 2013 .

Design, synthesis, and evaluation of 3,4-dihydro-2H-[1,4]diazepino[6,7,1-hi]indol-1-ones as inhibitors of poly(ADP-ribose) polymerase.

N. Curtin, R. Griffin, B. Golding, 2004, Journal of medicinal chemistry.

Anticancer chemosensitization and radiosensitization by the novel poly(ADP-ribose) polymerase-1 inhibitor AG14361.

Robert Almassy, Kaye J Williams, N. Curtin, 2004, Journal of the National Cancer Institute.

Therapeutic potential of poly(ADP-ribose) polymerase inhibitor AG014699 in human cancers with mutated or methylated BRCA1 or BRCA2.

Y. Drew, N. Curtin, Z. Hostomský, 2011, Journal of the National Cancer Institute.

Selective DNA-PKcs inhibition extends the therapeutic index of localized radiotherapy and chemotherapy

A. Ryan, H. Reeves, S. Wedge, 2019, The Journal of clinical investigation.

Development of a Functional Assay for Homologous Recombination Status in Primary Cultures of Epithelial Ovarian Tumor and Correlation with Sensitivity to Poly(ADP-Ribose) Polymerase Inhibitors

Y. Drew, N. Curtin, Z. Hostomský, 2010, Clinical Cancer Research.

Therapeutics , Targets , and Chemical Biology Cancer Research 6-Thioguanine Selectively Kills BRCA 2-Defective Tumors and Overcomes PARP Inhibitor Resistance

A. Harris, N. Curtin, Ricky A. Sharma, 2010 .

Identification and evaluation of a potent novel ATR inhibitor, NU6027, in breast and ovarian cancer cell lines

J. Sarkaria, N. Curtin, W. Cliby, 2011, British Journal of Cancer.

Preclinical selection of a novel poly(ADP-ribose) polymerase inhibitor for clinical trial

N. Curtin, D. Newell, Lan Z. Wang, 2007, Molecular Cancer Therapeutics.

6-thioguanine selectively kills BRCA2-defective tumors and overcomes PARP inhibitor resistance.

A. Harris, N. Curtin, Ricky A. Sharma, 2010, Cancer research.

Preclinical Evaluation of a Novel ATM Inhibitor, KU59403, In Vitro and In Vivo in p53 Functional and Dysfunctional Models of Human Cancer

N. Curtin, A. Lau, Yan Zhao, 2013, Molecular Cancer Therapeutics.

Exploiting the Achilles heel of cancer: the therapeutic potential of poly(ADP-ribose) polymerase inhibitors in BRCA2-defective cancer.

N. Curtin, S. Kyle, H. Thomas, 2008, The British journal of radiology.

Novel tricyclic poly(ADP-ribose) polymerase-1 inhibitors with potent anticancer chemopotentiating activity: design, synthesis, and X-ray cocrystal structure.

N. Curtin, R. Griffin, B. Golding, 2002, Journal of medicinal chemistry.

Wortmannin is a potent inhibitor of DNA double strand break but not single strand break repair in Chinese hamster ovary cells.

S. Boulton, B. Durkacz, L. Yalcintepe, 1996, Carcinogenesis.

Identification of potent nontoxic poly(ADP-Ribose) polymerase-1 inhibitors: chemopotentiation and pharmacological studies.

N. Curtin, B. Durkacz, D. Newell, 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

Anti-cancer chemosensitization in vitro and in vivo by a novel potent poly(ADP-ribose) polymerase (PARP1) inhibitor, TBI-361.

N. Curtin, S. Barton, R. Griffin, 2001 .

Tumour cell retention of rucaparib, sustained PARP inhibition and efficacy of weekly as well as daily schedules

J. Murray, A. Boddy, N. Curtin, 2014, British Journal of Cancer.

Novel Poly(ADP-ribose) Polymerase-1 Inhibitor, AG14361, Restores Sensitivity to Temozolomide in Mismatch Repair-Deficient Cells

N. Curtin, B. Durkacz, D. Newell, 2004, Clinical Cancer Research.